Cargando…
Can we establish a hierarchy among trastuzumab biosimilar candidates?
The European patent for intravenous trastuzumab lapsed in 2017, and this stimulated research into a number of trastuzumab biosimilars. Quality assessment of their development and clinical results might enable establishment of a clinical hierarchy of these agents. This editorial will underline the ke...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068097/ https://www.ncbi.nlm.nih.gov/pubmed/30002436 http://dx.doi.org/10.1038/s41416-018-0171-1 |